ecDNA在小细胞肺癌致癌相关性、异质性和耐药性的机制研究进展  

Research progress on the mechanisms of carcinogenic correlation,heterogeneity,and drug resistance of extrachromosomal DNA in small cell lung cancer

作　　者：杜威 陆瑶 陆亚兴(综述) 董秀娟(审校)[1] Wei Du;Yao Lu;Yaxing Lu;Xiujuan Dong(Integrated Traditional Chinese and Western Clinical Medicine,Traditional Chinese Medical College,Hainan Medical University,Haikou 571000,China;Integrated Traditional Chinese and Western Clinical Medicine,Guangzhou Medical University,Guangzhou 510000,China)

机构地区：[1]海南医学院中医学院中西医临床医学系,海口市571000 [2]广州医科大学中西医临床医学系

出　　处：《中国肿瘤临床》2024年第4期203-208,共6页Chinese Journal of Clinical Oncology

摘　　要：随着染色体外DNA(extrachromosomal DNA,ecDNA)研究的深入,研究发现ecDNA大多只存在于肿瘤细胞内,并且在肿瘤异质性和耐药中起着关键作用。ecDNA存在于多种恶性肿瘤中,但在正常细胞中极少出现。因为ecDNA具有强大的癌基因扩增和动态改变能力,故肿瘤细胞中含有ecDNA的患者临床预后更差。目前的研究已经证实小细胞肺癌(small cell lung cancer,SCLC)患者癌细胞中存在ecDNA。本文综述了ecDNA的形成机制并以此为基础讨论了ecDNA在癌细胞中扩增的过程,其促进肿瘤生长,复发和转移的机制以及ecDNA与SCLC高耐药性的关系。最后本文总结了ecDNA富集的SCLC的治疗方向,为未来进一步的研究提供一定指导。With the progression of research on extrachromosomal DNA(ecDNA),it has been shown that ecDNA exists mainly in tumor cells and plays a crucial role in tumor heterogeneity and drug resistance.ecDNA is observed in several cancer types,but rarely in normal cells.Due to their strong oncogene amplification and dynamic alteration capabilities,patients with ecDNA-containing tumor cells often have negative clinical prognoses.Research has confirmed the presence of ecDNA in the cancer cells of patients with small cell lung cancer(SCLC).This review provides a comprehensive summary of the formation mechanism of ecDNA,the processes through which it is amplified in cancer cells,the mechanisms through which ecDNA promotes tumor growth,recurrence,and metastasis,and its relationship with high drug resistance in SCLC.Finally,we generalize the treatment direction for ecDNA-enriched SCLCs,thereby guiding future research.

关 键 词：ecDNA 小细胞肺癌 肿瘤异质性 癌基因扩增 耐药性 

分 类 号：R734.2[医药卫生—肿瘤]